Drug Trial Radar · NCT00561951
Dose-Finding Study To Evaluate The Efficacy, Tolerability And Safety Of Fesoterodine In Comparison To Placebo For Overactive Bladder.
Last checked: Nov 20, 2026Latest source record: Jul 14, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
951
Actual
Start
Nov 2007
Primary completion
Jan 2009
Study completion Jan 2009
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 21, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.
Conditions
- Overactive Bladder
Interventions
fesoterodine fumarateDrug
8mg tablets OD for 12 weeks
PlaceboDrug
Corresponding placebo tablets OD for 12 weeks
fesoterodine fumarateDrug
4mg tablets OD for 12 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12.Time frame: Baseline to Week 12
Locations
65 sites in 4 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Kowloon, Hong Kong
Pfizer Investigational Site
Shatin, Hong Kong
Pfizer Investigational Site
Nagoya, Aichi-ken, Japan
Pfizer Investigational Site
Chuo-ku, Chiba-shi, Chiba, Japan
Pfizer Investigational Site
Eiheiji-cyo,yoshida-gun,, Fukui, Japan
Pfizer Investigational Site
Fukuoka, Fukuoka, Japan
Pfizer Investigational Site
Koga-shi, Fukuoka, Japan
Pfizer Investigational Site
Minami-ku, Fukuoka-shi, Fukuoka, Japan
Pfizer Investigational Site
Nishiku, Fukuoka, Japan
Pfizer Investigational Site
Sawara-ku, Fukuoka, Japan
Pfizer Investigational Site
Amagasaki-shi, Hyōgo, Japan
Pfizer Investigational Site
Higashinada, Hyōgo, Japan
Pfizer Investigational Site
Nada-ku, Kobe-shi, Hyōgo, Japan
Pfizer Investigational Site
Suma-ku, Kobe-shi, Hyōgo, Japan
Pfizer Investigational Site
Takaraduka-city, Hyōgo, Japan
Pfizer Investigational Site
Aira-gun, Aira-chou,, Kagoshima-ken, Japan
Pfizer Investigational Site
Isogo-ku, Yokohama-shi, Kanagawa, Japan
Pfizer Investigational Site
Kawasakishi, Kanagawa, Japan
Pfizer Investigational Site
Sagamihara-shi, Kanagawa, Japan
Pfizer Investigational Site
Tama-ku, Kawasaki-shi, Kanagawa, Japan
Pfizer Investigational Site
Kochi, Kochi, Japan
Pfizer Investigational Site
Kumamoto, Kumamoto, Japan
Pfizer Investigational Site
Tamana-shi, Kumamoto, Japan
Pfizer Investigational Site
Matsumoto-shi, Nagano, Japan
Pfizer Investigational Site
Matumoto-Shi, Nagano, Japan
Pfizer Investigational Site
Hunaki-cho, Ibaraki-shi, Osaka, Japan
Pfizer Investigational Site
Kita-ku, Osaka-shi, Osaka, Japan
Pfizer Investigational Site
Kosobe-cho, Takatsuki-shi, Osaka, Japan
Pfizer Investigational Site
Minami-ku, Sakai-shi, Osaka, Japan
Pfizer Investigational Site
Nishinari-ku, Osaka, Japan
Pfizer Investigational Site
Osaka, Osaka, Japan
Pfizer Investigational Site
Suita-shi, Osaka, Japan
Pfizer Investigational Site
Suita-shi,, Osaka, Japan
Pfizer Investigational Site
Toyonaka, Osaka, Japan
Pfizer Investigational Site
Yodogawa-Ku, Osaka, Japan
Pfizer Investigational Site
Saitama-shi, Saitama, Japan
Pfizer Investigational Site
Satte-shi, Saitama, Japan
Pfizer Investigational Site
Wakou-shi, Saitama, Japan
Pfizer Investigational Site
Gotenbashi, Shizuoka, Japan
Pfizer Investigational Site
Susono, Shizuoka, Japan
Showing 40 of 65 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.